PE20252763A1 - Medicamento de combinacion fija para el control y manejo del dolor neuropatico - Google Patents
Medicamento de combinacion fija para el control y manejo del dolor neuropaticoInfo
- Publication number
- PE20252763A1 PE20252763A1 PE2023002012A PE2023002012A PE20252763A1 PE 20252763 A1 PE20252763 A1 PE 20252763A1 PE 2023002012 A PE2023002012 A PE 2023002012A PE 2023002012 A PE2023002012 A PE 2023002012A PE 20252763 A1 PE20252763 A1 PE 20252763A1
- Authority
- PE
- Peru
- Prior art keywords
- management
- pharmaceutically acceptable
- control
- neuropathic pain
- fixed combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2020/050050 WO2022119430A1 (es) | 2020-12-04 | 2020-12-04 | Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20252763A1 true PE20252763A1 (es) | 2025-12-22 |
Family
ID=81853431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002012A PE20252763A1 (es) | 2020-12-04 | 2023-07-04 | Medicamento de combinacion fija para el control y manejo del dolor neuropatico |
| PE2023002013A PE20252750A1 (es) | 2020-12-04 | 2023-07-04 | Composicion farmaceutica solida recubierta y estable de un analgesico opioide y un antiepileptico para el dolor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002013A PE20252750A1 (es) | 2020-12-04 | 2023-07-04 | Composicion farmaceutica solida recubierta y estable de un analgesico opioide y un antiepileptico para el dolor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240000727A1 (https=) |
| EP (1) | EP4230199A4 (https=) |
| JP (1) | JP7720911B2 (https=) |
| KR (1) | KR20230117591A (https=) |
| CA (1) | CA3199166A1 (https=) |
| CO (1) | CO2023008896A2 (https=) |
| DO (1) | DOP2023000095A (https=) |
| MX (1) | MX2022015331A (https=) |
| PE (2) | PE20252763A1 (https=) |
| WO (1) | WO2022119430A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637767A (en) | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US20020187996A1 (en) | 2001-05-14 | 2002-12-12 | Dewey Stephen L. | Prevention of addiction in pain management |
| KR20060108692A (ko) | 2003-10-31 | 2006-10-18 | 알자 코포레이션 | 메트포르민의 개선된 흡수를 위한 조성물 및 제형 |
| MX2007008833A (es) | 2005-01-21 | 2008-03-25 | Pharmanova Inc | Formulaciones farmaceuticas y metodos de uso. |
| JP2007018123A (ja) | 2005-07-06 | 2007-01-25 | Kyocera Mita Corp | 画像処理装置、及び画像処理システム |
| MXPA05011735A (es) | 2005-11-01 | 2007-04-30 | Leopoldo Espinosa Abdala | Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico. |
| DE102007019071A1 (de) | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin |
| CL2008003800A1 (es) | 2007-12-21 | 2010-01-22 | Synthon Bv | Sal de acido sulfonico de pregabalina, procedimiento de preparacion, composicion farmaceutica, util para tratar trastornos neuropsiquiatricos, esquizofrenia, epilepsia, fibromialgia, trastorno de ansiedad generalizada, trastorno de panico y fobia social y dolor por ejemplo dolor neuropatico. |
| TR200909613A1 (tr) | 2009-12-22 | 2011-07-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Pregabalinin farmasötik bileşimleri. |
| AU2011276170B2 (en) | 2010-07-06 | 2016-03-10 | Grunenthal Gmbh | Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid |
| US20130189354A1 (en) | 2010-10-07 | 2013-07-25 | Trinity Laboratories, Inc., | Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy |
| US20150313892A1 (en) * | 2014-02-07 | 2015-11-05 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating pain associated with dysmenorrhea |
| WO2018015946A1 (en) | 2016-07-17 | 2018-01-25 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
| MX2017016720A (es) | 2017-12-19 | 2019-06-20 | Monte Verde S A | Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba). |
| KR20190075718A (ko) * | 2017-12-21 | 2019-07-01 | 주식회사 네비팜 | 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제 |
| WO2020044070A1 (es) * | 2018-08-30 | 2020-03-05 | Grünenthal GmbH | Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático |
-
2020
- 2020-12-04 US US18/255,244 patent/US20240000727A1/en active Pending
- 2020-12-04 CA CA3199166A patent/CA3199166A1/en active Pending
- 2020-12-04 JP JP2023532743A patent/JP7720911B2/ja active Active
- 2020-12-04 EP EP20964395.6A patent/EP4230199A4/en active Pending
- 2020-12-04 MX MX2022015331A patent/MX2022015331A/es unknown
- 2020-12-04 KR KR1020237022683A patent/KR20230117591A/ko active Pending
- 2020-12-04 WO PCT/MX2020/050050 patent/WO2022119430A1/es not_active Ceased
-
2023
- 2023-05-12 DO DO2023000095A patent/DOP2023000095A/es unknown
- 2023-07-04 CO CONC2023/0008896A patent/CO2023008896A2/es unknown
- 2023-07-04 PE PE2023002012A patent/PE20252763A1/es unknown
- 2023-07-04 PE PE2023002013A patent/PE20252750A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3199166A1 (en) | 2022-06-09 |
| MX2022015331A (es) | 2023-02-01 |
| PE20252750A1 (es) | 2025-12-05 |
| JP7720911B2 (ja) | 2025-08-08 |
| WO2022119430A1 (es) | 2022-06-09 |
| KR20230117591A (ko) | 2023-08-08 |
| JP2024504902A (ja) | 2024-02-02 |
| EP4230199A1 (en) | 2023-08-23 |
| US20240000727A1 (en) | 2024-01-04 |
| EP4230199A4 (en) | 2024-07-31 |
| DOP2023000095A (es) | 2023-06-15 |
| CO2023008896A2 (es) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| MXPA03010991A (es) | Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. | |
| UY27532A1 (es) | Forma de dosificación de liberación controlada dual. | |
| CO5640072A2 (es) | Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion | |
| AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| CL2022003512A1 (es) | Formas farmacéuticas osmóticas que comprenden deutetrabenazina y métodos de uso de las mismas | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| JP2022551691A5 (https=) | ||
| CR7049A (es) | Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol | |
| MX2023003097A (es) | Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral. | |
| PE20252763A1 (es) | Medicamento de combinacion fija para el control y manejo del dolor neuropatico | |
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| AR046146A1 (es) | Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso | |
| AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
| JP2025507472A5 (https=) | ||
| CO2025007025A2 (es) | Formulaciones orales compactables de ibutamoren | |
| MX2021011795A (es) | Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble. | |
| ECSP003685A (es) | Formulaciones orales de liberacion controlada | |
| AR132497A1 (es) | Combinación de obicetrapib amorfo e inhibidor de sglt2 | |
| AR052567A1 (es) | Combinacion de bambuterol e inhibidor de integrina | |
| ES2572180T3 (es) | Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada |